<code id='AA899A3FCE'></code><style id='AA899A3FCE'></style>
    • <acronym id='AA899A3FCE'></acronym>
      <center id='AA899A3FCE'><center id='AA899A3FCE'><tfoot id='AA899A3FCE'></tfoot></center><abbr id='AA899A3FCE'><dir id='AA899A3FCE'><tfoot id='AA899A3FCE'></tfoot><noframes id='AA899A3FCE'>

    • <optgroup id='AA899A3FCE'><strike id='AA899A3FCE'><sup id='AA899A3FCE'></sup></strike><code id='AA899A3FCE'></code></optgroup>
        1. <b id='AA899A3FCE'><label id='AA899A3FCE'><select id='AA899A3FCE'><dt id='AA899A3FCE'><span id='AA899A3FCE'></span></dt></select></label></b><u id='AA899A3FCE'></u>
          <i id='AA899A3FCE'><strike id='AA899A3FCE'><tt id='AA899A3FCE'><pre id='AA899A3FCE'></pre></tt></strike></i>

          
          WSS

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot